NSG533/ NSG 533 Exam 3 (Latest
2026/2027 Update) Complete Study
Guide with Verified Q&A and Detailed
Rationales Respiratory Pharmacology
NSG533/ NSG 533 Exam 3 (Latest 2026/2027 | Comprehensive
Examination
NSG533/ NSG 533 Exam 3 (Latest 2026/2027 Update)
Complete Study Guide with Verified Q&A and Detailed
Rationales Respiratory Pharmacology A+ Graded Wilkes
INTRODUCTION
This document is an important and very helpful preparation
resource for NSG533/ NSG 533 Exam 3 (Latest 2026/2027
Update) Complete Study Guide with Verified Q&A and Detailed
Rationales Respiratory Pharmacology A+ Graded Wilkes
University. Every item uses a focused exam stem, four response
options, a keyed response, and a clear rationale, making it
easier to understand the subject, spot distractors, and build real
exam confidence.
Page 1
, Question 1
Which statement best explains why a patient with acute severe bronchospasm
may fail to respond to inhaled albuterol despite adequate dosing?
A. Beta-2 receptors are downregulated only after chronic systemic
corticosteroid use.
B. Severe airway obstruction and poor inspiratory flow reduce peripheral
aerosol deposition.
C. Albuterol becomes a beta-1 antagonist under acidic airway conditions.
D. Mucosal edema increases alveolar absorption of albuterol, causing
tachyphylaxis.
Correct Answer: B - Severe airway obstruction and poor
inspiratory flow reduce peripheral aerosol deposition.
RATIONALE
In severe bronchospasm, turbulent flow and air trapping limit aerosol
penetration to small airways, so even correct technique yields low
lung deposition. Receptor downregulation is not the primary acute
issue, albuterol does not switch receptor selectivity, and edema does
not enhance absorption.
Question 2
A patient with COPD and a history of benign prostatic hyperplasia reports
increased urinary retention after starting a new inhaler. Which agent is most
likely responsible?
A. Salmeterol
B. Ipratropium
C. Fluticasone
D. Montelukast
Correct Answer: B - Ipratropium
Page 2
, RATIONALE
Ipratropium is an inhaled anticholinergic that can worsen urinary
retention in BPH by reducing detrusor contractility. Salmeterol,
fluticasone, and montelukast do not have significant anticholinergic
urinary effects.
Question 3
Which pharmacodynamic property best distinguishes roflumilast from inhaled
corticosteroids in COPD management?
A. Roflumilast directly bronchodilates via beta-2 agonism.
B. Roflumilast inhibits phosphodiesterase-4, reducing inflammation
without immunosuppression.
C. Roflumilast blocks leukotriene receptors to prevent
bronchoconstriction.
D. Roflumilast suppresses adrenal cortisol synthesis more than ICS.
Correct Answer: B - Roflumilast inhibits phosphodiesterase-4,
reducing inflammation without immunosuppression.
RATIONALE
Roflumilast is a PDE-4 inhibitor that reduces airway inflammation and
exacerbations without the broad immunosuppressive effects of
corticosteroids. It is not a bronchodilator, leukotriene antagonist, or
adrenal suppressant.
Question 4
A patient using a dry powder inhaler (DPI) achieves poor symptom control.
Which factor most likely explains this?
A. The patient uses a spacer with the DPI.
B. The patient's peak inspiratory flow is insufficient to disaggregate the
powder.
C. The patient exhales fully before inhalation.
Page 3
, D. The patient rinses the mouth after each dose.
Correct Answer: B - The patient's peak inspiratory flow is
insufficient to disaggregate the powder.
RATIONALE
DPIs require adequate inspiratory flow to deaggregate drug particles;
low flow reduces lung deposition. Spacers are not used with DPIs,
exhaling before inhalation is correct technique, and mouth rinsing
does not impair delivery.
Question 5
Which mechanism explains the additive benefit of adding a long-acting
muscarinic antagonist (LAMA) to a LABA in COPD?
A. LAMAs increase beta-2 receptor sensitivity.
B. LAMAs block M3 receptors, reducing vagal bronchoconstriction and
mucus secretion.
C. LAMAs inhibit phosphodiesterase-4, enhancing bronchodilation.
D. LAMAs directly stimulate beta-2 receptors in small airways.
Correct Answer: B - LAMAs block M3 receptors, reducing vagal
bronchoconstriction and mucus secretion.
RATIONALE
LAMAs antagonize M3 muscarinic receptors, decreasing vagally
mediated bronchoconstriction and mucus secretion, which
complements LABA-mediated beta-2 agonism. They do not sensitize
beta-2 receptors, inhibit PDE-4, or stimulate beta-2 receptors.
Question 6
A patient with severe asthma is started on mepolizumab. Which baseline
finding best predicts a favorable response?
A. Blood eosinophils 150 cells/µL at initiation
B. Serum IgE >700 IU/mL
Page 4
2026/2027 Update) Complete Study
Guide with Verified Q&A and Detailed
Rationales Respiratory Pharmacology
NSG533/ NSG 533 Exam 3 (Latest 2026/2027 | Comprehensive
Examination
NSG533/ NSG 533 Exam 3 (Latest 2026/2027 Update)
Complete Study Guide with Verified Q&A and Detailed
Rationales Respiratory Pharmacology A+ Graded Wilkes
INTRODUCTION
This document is an important and very helpful preparation
resource for NSG533/ NSG 533 Exam 3 (Latest 2026/2027
Update) Complete Study Guide with Verified Q&A and Detailed
Rationales Respiratory Pharmacology A+ Graded Wilkes
University. Every item uses a focused exam stem, four response
options, a keyed response, and a clear rationale, making it
easier to understand the subject, spot distractors, and build real
exam confidence.
Page 1
, Question 1
Which statement best explains why a patient with acute severe bronchospasm
may fail to respond to inhaled albuterol despite adequate dosing?
A. Beta-2 receptors are downregulated only after chronic systemic
corticosteroid use.
B. Severe airway obstruction and poor inspiratory flow reduce peripheral
aerosol deposition.
C. Albuterol becomes a beta-1 antagonist under acidic airway conditions.
D. Mucosal edema increases alveolar absorption of albuterol, causing
tachyphylaxis.
Correct Answer: B - Severe airway obstruction and poor
inspiratory flow reduce peripheral aerosol deposition.
RATIONALE
In severe bronchospasm, turbulent flow and air trapping limit aerosol
penetration to small airways, so even correct technique yields low
lung deposition. Receptor downregulation is not the primary acute
issue, albuterol does not switch receptor selectivity, and edema does
not enhance absorption.
Question 2
A patient with COPD and a history of benign prostatic hyperplasia reports
increased urinary retention after starting a new inhaler. Which agent is most
likely responsible?
A. Salmeterol
B. Ipratropium
C. Fluticasone
D. Montelukast
Correct Answer: B - Ipratropium
Page 2
, RATIONALE
Ipratropium is an inhaled anticholinergic that can worsen urinary
retention in BPH by reducing detrusor contractility. Salmeterol,
fluticasone, and montelukast do not have significant anticholinergic
urinary effects.
Question 3
Which pharmacodynamic property best distinguishes roflumilast from inhaled
corticosteroids in COPD management?
A. Roflumilast directly bronchodilates via beta-2 agonism.
B. Roflumilast inhibits phosphodiesterase-4, reducing inflammation
without immunosuppression.
C. Roflumilast blocks leukotriene receptors to prevent
bronchoconstriction.
D. Roflumilast suppresses adrenal cortisol synthesis more than ICS.
Correct Answer: B - Roflumilast inhibits phosphodiesterase-4,
reducing inflammation without immunosuppression.
RATIONALE
Roflumilast is a PDE-4 inhibitor that reduces airway inflammation and
exacerbations without the broad immunosuppressive effects of
corticosteroids. It is not a bronchodilator, leukotriene antagonist, or
adrenal suppressant.
Question 4
A patient using a dry powder inhaler (DPI) achieves poor symptom control.
Which factor most likely explains this?
A. The patient uses a spacer with the DPI.
B. The patient's peak inspiratory flow is insufficient to disaggregate the
powder.
C. The patient exhales fully before inhalation.
Page 3
, D. The patient rinses the mouth after each dose.
Correct Answer: B - The patient's peak inspiratory flow is
insufficient to disaggregate the powder.
RATIONALE
DPIs require adequate inspiratory flow to deaggregate drug particles;
low flow reduces lung deposition. Spacers are not used with DPIs,
exhaling before inhalation is correct technique, and mouth rinsing
does not impair delivery.
Question 5
Which mechanism explains the additive benefit of adding a long-acting
muscarinic antagonist (LAMA) to a LABA in COPD?
A. LAMAs increase beta-2 receptor sensitivity.
B. LAMAs block M3 receptors, reducing vagal bronchoconstriction and
mucus secretion.
C. LAMAs inhibit phosphodiesterase-4, enhancing bronchodilation.
D. LAMAs directly stimulate beta-2 receptors in small airways.
Correct Answer: B - LAMAs block M3 receptors, reducing vagal
bronchoconstriction and mucus secretion.
RATIONALE
LAMAs antagonize M3 muscarinic receptors, decreasing vagally
mediated bronchoconstriction and mucus secretion, which
complements LABA-mediated beta-2 agonism. They do not sensitize
beta-2 receptors, inhibit PDE-4, or stimulate beta-2 receptors.
Question 6
A patient with severe asthma is started on mepolizumab. Which baseline
finding best predicts a favorable response?
A. Blood eosinophils 150 cells/µL at initiation
B. Serum IgE >700 IU/mL
Page 4
